{
    "clinical_study": {
        "@rank": "10185", 
        "brief_summary": {
            "textblock": "The combination of Anidulafungin plus AmBisome\u00ae may offer an improved outcome for patients\n      treated for Invasive Aspergillosis (IA). The purpose of this study is to determine the\n      safety and the clinical and microbiological effectiveness of anidulafungin plus AmBisome\u00ae in\n      treated patients located in the United States, Europe, and South Africa."
        }, 
        "brief_title": "A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome\u00ae for Treatment of Invasive Aspergillosis (IA).", 
        "completion_date": {
            "#text": "February 2003", 
            "@type": "Actual"
        }, 
        "condition": "Aspergillosis", 
        "condition_browse": {
            "mesh_term": "Aspergillosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of definite IA outside the pulmonary system or definite or probable\n             pulmonary IA\n\n          -  Life expectancy:  greater than 72 hours\n\n        Exclusion Criteria:\n\n          -  Pregnant female\n\n          -  Hypersensitivity to anidulafungin or echinocandin therapy\n\n          -  Hypersensitivity to Tween 80 (polysorbate 80) or tartaric acid\n\n          -  Hypersensitivity to amphotericin B deoxycholate or any other constituents of AmBisome\n             unless, in the opinion of the investigator, the benefit of therapy outweighs the\n             risk.\n\n          -  Aspergilloma-in the absence of invasive disease\n\n          -  Abnormal blood chemistries:\n\n        Bilirubin > 3 times the upper limit of normal; AST (aspartate aminotransferase) or ALT\n        (alanine aminotransferase)> 5 times the upper limit of normal\n\n          -  Greater than five days of therapeutic doses of systemic therapy for the current\n             Aspergillus-associated condition or a cumulative dose of more than 5 mg/Kg of\n             amphotericin, more than 25 mg/Kg of a lipid formulation of amphotericin, or more than\n             2g of itraconazole for the current condition.  Prophylactic use of azoles or\n             amphotericin is acceptable.\n\n          -  Less than 4 weeks since prior participation in an investigational drug or device\n             study, with the exception of cytotoxic, antiretroviral agents and therapies for\n             AIDS-related opportunistic infections."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 16, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00037206", 
            "org_study_id": "VER002-7", 
            "secondary_id": "A8851001"
        }, 
        "intervention": {
            "intervention_name": "Anidulafungin, VER002", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Liposomal amphotericin B", 
                "Anidulafungin", 
                "Echinocandins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "keyword": "Invasive Aspergillosis", 
        "lastchanged_date": "October 17, 2008", 
        "location": {
            "facility": {
                "address": {
                    "city": "King of Prussia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19406"
                }, 
                "name": "Versicor, Inc."
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "An Open Label Non-Comparative Study of the Safety and Efficacy of Intravenous Anidulafungin Plus AmBisome\u00ae [(Amphotericin B) Liposome for Injection] as a Treatment for Invasive Aspergillosis.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2/Phase 3", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00037206"
        }, 
        "responsible_party": {
            "name_title": "Director, Clinical Trial Disclosure Group", 
            "organization": "Pfizer, Inc."
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "collaborator": {
                "agency": "Vicuron Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2002", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2008"
    }, 
    "geocoordinates": {
        "Versicor, Inc.": "40.089 -75.396"
    }
}